SPRY
ARS Pharmaceuticals, Inc
4.10$
-1.7%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | 1,379.2% | 5.4% | 4.5% | 50.7% | 31.7% | 25.2% | 11.4% | 27.7% | 38.2% | 26.1% | |
| – | – | – | -1,279.2% | 94.6% | 95.5% | 49.3% | 68.3% | 74.8% | 88.6% | 72.3% | 61.8% | 73.9% | |
| – | – | – | 1,379.2% | 213.9% | 3.5% | 37.0% | 25.7% | 8.5% | 12.3% | 19.1% | 14.0% | 13.0% | |
| – | – | – | 1,788.8% | 932.4% | 41.8% | 515.5% | 345.6% | 230.0% | 213.5% | 318.3% | 230.5% | 243.3% | |
| – | – | – | 1,788.8% | 1,146.2% | 41.0% | 515.5% | 371.2% | 238.5% | 236.2% | 337.5% | 244.5% | 258.9% | |
| – | – | – | -3,068.0% | -1,051.6% | 54.5% | -466.3% | -302.9% | -163.7% | -147.6% | -265.2% | -182.6% | -185.0% | |
| – | – | – | – | – | – | 0.0% | 0.0% | – | 9.3% | 10.8% | 7.4% | – | |
| – | – | – | -2,503.2% | -925.0% | 58.0% | -425.7% | -285.6% | -157.4% | -147.4% | -267.3% | -185.2% | -184.3% | |
| – | – | – | – | – | 0.3% | – | – | – | -0.3% | – | – | – | |
| – | – | – | -2,503.2% | -925.0% | 57.7% | -425.7% | -285.6% | -157.4% | -147.1% | -267.3% | -185.2% | -184.2% | |
| – | – | – | -2,499.6% | -923.9% | 58.0% | -422.2% | -283.8% | -150.1% | -145.9% | -254.8% | -176.6% | -177.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.